Nationwide Fund Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Nationwide Fund Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Hold	0	–	–	–	631
2017 Q3	–	Hold	0	–	–	–	3198
2017 Q2	–	Sell	-38	Closed	-$3.87K	–	3210
2017 Q1	$5K	Hold	38	–	–	﹤0.01%	3155
2016 Q4	$6K	Hold	38	–	–	﹤0.01%	3144
2016 Q3	$9K	Hold	38	–	–	﹤0.01%	3153
2016 Q2	$34K	Hold	38	–	–	﹤0.01%	3115
2016 Q1	$34K	Hold	38	–	–	﹤0.01%	3043
2015 Q4	$53K	Hold	38	–	–	﹤0.01%	2985
2015 Q3	$63K	Hold	38	–	–	﹤0.01%	2994
2015 Q2	$81K	Buy	38 +11	+41%	+$21.3K	﹤0.01%	3049
2015 Q1	$50K	Buy	27 +2	+8%	+$4.41K	﹤0.01%	3099
2014 Q4	$59K	Buy	+25	New	+$59.4K	﹤0.01%	3006

Other funds holding ELDN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Derby & Company Newton, Massachusetts $495M AUM 23.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Nationwide Fund Advisors's ELDN Position: Q4 2017 in Review

Nationwide Fund Advisors held its Eledon Pharmaceuticals (ELDN) position steady in Q4 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #631.

Nationwide Fund Advisors first reported a position in ELDN in Q4 2014 and has held it in 10 quarters since. The position peaked at $81K in Q2 2015. 11 funds tracked by Wall St. Rank hold ELDN as of Q4 2017.

Nationwide Fund Advisors held 0 shares of Eledon Pharmaceuticals worth $0 as of Q4 2017.
Nationwide Fund Advisors left its Eledon Pharmaceuticals share count unchanged in Q4 2017.
Eledon Pharmaceuticals made up ﹤0.01% of Nationwide Fund Advisors's portfolio in Q4 2017, its #631 holding.
Nationwide Fund Advisors first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 10 quarters since.
Nationwide Fund Advisors's Eledon Pharmaceuticals position peaked at $81K in Q2 2015.
11 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.